ARTICLE | Finance
Valuing CRISPR/Cas9
Editas seeks the biggest-ever valuation for a preclinical biotech IPO
February 1, 2016 8:00 AM UTC
Editas Medicine Inc. is looking for a $606.9 million postmoney valuation - the highest of any preclinical biotech IPO since BioCentury started tracking financings in 1994. Even if Editas takes the now-standard 20% IPO haircut, it still would hold the top slot.
According to BioCentury's BCIQ database, a preclinical biotech IPO has never garnered a postmoney valuation above $500 million. The current top slot is held by cancer company Blueprint Medicines Corp. (NASDAQ:BPMC), which went public last April with a valuation of $465 million. ...